AB Science Cuts Losses, Focuses on ALS and AML Trials Amid Financial Restructuring
Event summary
- AB Science reported a 38% reduction in operating loss to €3.8 million for 2025, driven by cost-cutting and non-recurring items.
- The company secured €3.2 million in April 2026 via a private placement, adding to its €10.2 million cash position as of December 2025.
- AB Science reached agreements to defer loan repayments, extending maturities and reducing immediate financial pressure.
- Clinical focus shifted to Phase 3 trials for masitinib in ALS and Phase 1 trials for AB8939 in AML, with other programs deprioritized.
- Maxim Group initiated coverage with a €4.00 target price, citing masitinib's potential in neurodegenerative diseases.
The big picture
AB Science's strategic pivot to focus on ALS and AML trials reflects a broader industry trend of biotech companies streamlining pipelines to conserve cash and enhance regulatory appeal. The financial restructuring, including deferred loan repayments and new equity funding, buys the company time to demonstrate clinical efficacy. Success in these trials could position AB Science for potential partnerships or acquisitions, but failure risks further financial strain.
What we're watching
- Trial Execution
- Whether AB Science can successfully execute its Phase 3 ALS trial with masitinib, given the stringent patient selection criteria and regulatory scrutiny.
- Financial Sustainability
- The pace at which AB Science can sustain its reduced operating loss while advancing its key clinical programs without additional funding rounds.
- Regulatory Pathways
- How the EMA and FDA will respond to AB Science's clinical trial designs and whether they will expedite approval processes for masitinib and AB8939.
Related topics